



05-07-02

1617
RECEIVED
CASE 430755B
MAY 10 2002
TECH CENTER 1600/2000
5/20/02

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV041586381US</u> Express Mail Label Number	<u>5/6/02</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1617

BULLOCK ET AL.

Examiner: Kim, J.

APPLICATION NO: 10/072,516

FILED: FEBRUARY 6, 2002

FOR: ADDITIONAL THERAPEUTIC USE

Assistant Commissioner for Patents
Washington, D.C. 20231

SECOND PRELIMINARY AMENDMENT

Sir:

Responsive to the outstanding Notice OF Non-Compliant Amendment dated April 25, 2002, in the above-identified application, having a period for response set to expire May 25, 2002, Applicant respectfully requests the following amendment be entered and the claims considered in light thereof.

IN THE SPECIFICATION

Please replace the paragraph beginning at page 3, line 12, with the following rewritten paragraph:

--PCR (Polymerase Chain Reaction) products were prepared and used as follows:
Oligonucleotides specific to human angiotensin II receptor type I (GenBank accession number M93394) and angiotensin II receptor type II (GenBank accession number U15592) were designed using the Oligo 5.0 software programme to homologous regions from both sequences (Table 1). CDNA from human bone tissue was prepared following standard methods (Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989). For PCR the following oligonucleotide primer pairs were used: angiotensin II receptor